203,044 Shares in Gilead Sciences, Inc. $GILD Acquired by Sanctuary Advisors LLC

Key Points

• Sanctuary Advisors acquired 203,044 Gilead shares during the second quarter, worth approximately $25.7 million. Institutional investors collectively own 83.67% of the company.
• Gilead reported quarterly revenue of $7.8 billion, up 10.6% year over year, and exceeded analysts’ EPS expectations despite posting a loss. The company also declared a quarterly dividend of $0.82 per share, yielding about 2.2% annually.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $158.04, while recent insider activity has been weighted toward selling, including transactions by the CEO and a director.

Sanctuary Advisors LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 203,044 shares of the biopharmaceutical company's stock, valued at approximately $25,653,000.

Several other institutional investors have also modified their holdings of GILD. Aviva PLC boosted its position in shares of Gilead Sciences by 5.4% during the 4th quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company's stock worth $141,978,000 after purchasing an additional 59,782 shares in the last quarter. Life Cycle Investment Partners Ltd purchased a new position in shares of Gilead Sciences in the 4th quarter valued at about $1,418,000. Bank of Nova Scotia purchased a new stake in Gilead Sciences during the second quarter worth about $100,056,000. Flputnam Investment Management Co. lifted its position in shares of Gilead Sciences by 66.5% during the 4th quarter. Flputnam Investment Management Co. now owns 105,740 shares of the biopharmaceutical company's stock valued at $12,978,000 after acquiring an additional 42,243 shares during the period. Finally, Harvest Fund Management Co. Ltd lifted its position in shares of Gilead Sciences by 14.4% during the 4th quarter. Harvest Fund Management Co. Ltd now owns 106,526 shares of the biopharmaceutical company's stock valued at $13,075,000 after acquiring an additional 13,385 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $146.12 on Monday. The stock has a 50-day moving average price of $131.97 and a 200 day moving average price of $136.55. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The stock has a market cap of $181.18 billion, a PE ratio of -54.73 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm's quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.01 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post -0.51 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. Gilead Sciences's dividend payout ratio (DPR) is -122.85%.

Insiders Place Their Bets

In related news, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the transaction, the director directly owned 10,066 shares in the company, valued at approximately $1,459,771.32. This represents a 33.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 15,000 shares of Gilead Sciences stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the sale, the chief executive officer owned 592,133 shares of the company's stock, valued at $77,160,851.23. This trade represents a 2.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 87,000 shares of company stock worth $11,562,960 over the last ninety days. Company insiders own 0.30% of the company's stock.

Analysts Set New Price Targets

GILD has been the topic of a number of research reports. Cantor Fitzgerald restated an "overweight" rating and issued a $155.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Royal Bank Of Canada boosted their target price on Gilead Sciences from $120.00 to $123.00 and gave the stock a "sector perform" rating in a research report on Wednesday, August 5th. Needham & Company LLC reissued a "buy" rating and issued a $170.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. Maxim Group upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price target for the company in a research report on Wednesday, May 20th. Finally, Leerink Partners lowered shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Twenty-four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $158.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source